Portland, OR (PRWEB) June 22, 2011
13therapeutics, Inc. has been selected to present at the 10th World Congress on Inflammation in Paris June 25-29, 2011. The World Congress on Inflammation is a biennial congress organized by the International Association of Inflammation Societies. This prestigious scientific conference attracts the world’s leading scientists who are doing research and development in the field of inflammation.
"Inflammation is part of the body’s biological response to harmful stimuli such as pathogens (viruses, bacteria, fungi), damaged cells, or irritants. It is a protective attempt by the body to remove the injurious stimuli and to initiate the healing process. However, prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process. Chronic inflammation is an underlying cause of auto-immune diseases like Rheumatoid Arthritis, Lupus and Crohn’s Disease. It is also thought to play a role in the development of heart disease and Alzheimer’s disease," said Dr. Steven Hefeneider, President and CSO.
“We are very pleased to have been selected to present at this highly regarded scientific conference,” said Dr. Hefeneider. “It is a strong validation of the quality and importance of our science, and it closely follows our recent presentation at the International Symposium on Recent Advances in Otitis Media, another highly regarded scientific conference.”
13therapeutics has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the company’s peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features of clinical therapeutics.
13therapeutics (http://www.13therapeutics.com) is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. Founded in 2008, the Portland, Oregon-based company is a spin-out from the Oregon Health and Science University (OHSU). The management team and research scientists of 13therapeutics are veterans of bioscience, research and technology.